Fatal Case Of Solid Organ Infarcts In a Case Of Myelodysplastic Syndrome (MDS) With Refractory Anaemia



Read Counter
586

Downloads
573

Citations

Share

Article Sidebar

Submitted 2020-04-03
Published 2020-05-01
10.24018/ejmed.2020.2.3.230

Read counter = 586 times

Table of Contents

Article Main Content

Myelodysplastic syndrome (MDS) usually presents with cytopenias  because of bone marrow failure. Solid organ infarcts in myelodysplastic syndrome (MDS) is rarest complication. We report an elderly male, admitted with complaints of pain abdomen mainly in both flanks and swelling all over the body. Peripheral  blood smear, bone marrow aspirate for cytology were suggestive of myelodysplastic syndrome(MDS) with refractory anaemia. Fluorescence in situ hybridization(FISH) were negative for any chromosomal abnormalities. His CECT abdomen was done which revealed hepatosplenomegaly with hyperdense liver with multiple splenic and renal infarcts and patient was treated as a case of MDS with refractory anaemia with solid organ infarcts. Over a period of 3 days, he had Acute Kidney Injury (AKI).  Patient succumbed on fifth day.

Keywords: Myelodysplastic syndrome (MDS), renal infarct, splenic infarct, a case report.

References

  1. Dansey R. Myelodysplasia. Curr. Opin. Oncol. 2000; 12: 13–21 [Crossref], [PubMed], [Web of Science ®], [Google Scholar]
    DOI  |   Google Scholar
  2. Lowenthal R.M., Marsden K.A. Myelodysplastic syndromes. Int. J. Hematol. 1997; 65: 319–338 [Crossref], [PubMed], [Web of Science ®], [Google Scholar]
     Google Scholar
  3. Mittelman M., Zeidman A. Platelet function in myelodysplastic syndromes. Int. J. Hematol. 2000; 71: 95–98 [Google Scholar]
     Google Scholar
  4. Swarna Sri Nalluru, Vishal Jindal, Paramarajan Piranavan, Yugandhara Kate, and Ahmad D. Siddiqui, Splenic infarction secondary to myelodysplastic syndrome: unravelling more etiologies.
     Google Scholar
  5. Hyun Woo Bae, Hyun Dong Kim, Sung Won Choi, Nami Han, Mi Ja Eom, Acute Cerebral Infarction as a Rare Thrombotic Event in Myelodysplastic Syndrome: A Case Report.
     Google Scholar
  6. MN Niazy*, TI Neyyarapally**, A Chattopadhyay***Erythropoietin-Induced Deep Vein Thrombosis in Myelodysplastic Syndrome.
     Google Scholar
  7. Wurthner, J.U.;kohler,G.;Behringer, D.;Lindemann, A.; Mertelsmann, R.;Lubbert, M. Leukostasis followed by haemorrhage complicating the initation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis. Cancer 1999,85, 368-374
    DOI  |   Google Scholar
  8. Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood. 2002;100:4427–4432. [PubMed] [Google Scholar]
    DOI  |   Google Scholar
  9. Labardini JR, Hernández MC, Cervera E, et al., “Síndromes mielodisplásicos”. Instituto Nacional de Cancerología, vol.6: 129-32, 2011.
     Google Scholar
  10. De La Mora O, Guerrero S, García V, et al., “Guia de practica clinica diagnóstico y tratamiento de sindrome mielodisplásico”. Catálogo maestro de GPC, Mëxico: 2010
     Google Scholar
  11. Pintos EN, Carbejo MdR, “Clasificación de los síndromes mielodisplásicos”. Hematología, vol.14, no.3: 86-90, 2010
     Google Scholar
  12. Tricot GJ, Lauer RC, Appelbaum FR, et al.: Management of the myelodysplastic syndromes. Semin Oncol 14 (4): 444-53, 1987.
     Google Scholar
  13. Boogaerts MA: Progress in the therapy of myelodysplastic syndromes. Blut 58 (6): 265-70, 1989.
    DOI  |   Google Scholar
  14. Park S, Grabar S, Kelaidi C, et al.: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and GCSF: the GFM experience. Blood 111 (2):574-82, 2008.
    DOI  |   Google Scholar
  15. Mannone L, Gardin C, Quarre MC, et al.: High dose darbepoetin alpha in the treatment of anemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133 (5): 513-9, 2006.
    DOI  |   Google Scholar
  16. Gabrilove J, Paquette R, Lyons RM, et al.: Phase 2, single-arm trail to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142 (3): 379-93, 2008.
    DOI  |   Google Scholar
  17. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al.: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92 (1): 68-75, 1998.
    DOI  |   Google Scholar
  18. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A: Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk res 21 (5): 415-25, 1997.
    DOI  |   Google Scholar
  19. Negrin RS, Stein R, Doherty K, et al.: Maintenance treatment of the anaemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87 (10) 4076-81, 1996.
    DOI  |   Google Scholar
  20. GreenbergPL, Rigsby CK, Stone RM, et al.: NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw 7 (suppl 9): S1-16, 2009.
    DOI  |   Google Scholar
  21. Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the Dusseldorf MDS-registry. Leuk Res.2011;35:1591-1596.
    DOI  |   Google Scholar